Laddar...
Discovery of PROTAC BCL-X(L) Degraders as Potent Anticancer Agents with Low On-target Platelet Toxicity
Anti-apoptotic protein BCL-X(L) plays a key role in tumorigenesis and cancer chemotherapy resistance, rendering it an attractive target for cancer treatment. However, BCL-X(L) inhibitors such as ABT-263 cannot be safely used in the clinic because platelets solely depend on BCL-X(L) to maintain their...
Sparad:
| I publikationen: | Eur J Med Chem |
|---|---|
| Huvudupphovsmän: | , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433031/ https://ncbi.nlm.nih.gov/pubmed/32145645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2020.112186 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|